{"id":51003,"date":"2025-12-16T23:20:07","date_gmt":"2025-12-16T15:20:07","guid":{"rendered":"https:\/\/flcube.com\/?p=51003"},"modified":"2025-12-16T23:20:09","modified_gmt":"2025-12-16T15:20:09","slug":"zhichengs-tavr-robotic-system-enters-nmpa-innovation-pathway","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51003","title":{"rendered":"Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway"},"content":{"rendered":"\n

Zhicheng Medical Technology (Jiaxing) Co., Ltd.<\/strong> announced that its self\u2011developed ReachTact Transcatheter Aortic Valve Replacement (TAVR) Surgical Assistance System<\/strong> has entered the National Medical Products Administration\u2019s (NMPA) Innovative Medical Device Special Review Pathway<\/strong>, becoming the first TAVR robotic system in China\u2019s structural heart disease field<\/strong> to achieve this status.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Entry Date<\/strong><\/td>15\u202fDec\u202f2025<\/td><\/tr>
Pathway<\/strong><\/td>NMPA Innovative Medical Device Special Review<\/td><\/tr>
Product<\/strong><\/td>ReachTact TAVR Surgical Assistance System<\/td><\/tr>
Significance<\/strong><\/td>First TAVR robotic system<\/strong> in China to enter the program<\/td><\/tr>
Expected Benefit<\/strong><\/td>Expedited review and approval process; potential for 3\u2011year market exclusivity<\/strong><\/td><\/tr>
Launch Timeline<\/strong><\/td>2027\u20112028<\/strong> (pending successful review)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Innovation & Technical Features<\/h2>\n\n\n\n
Feature<\/th>ReachTact System<\/th>Clinical Advantage<\/th><\/tr><\/thead>
Control System<\/strong><\/td>Master\u2011slave robotic control<\/td>Surgeon operates from radiation\u2011shielded environment<\/td><\/tr>
Precision<\/strong><\/td>Sub\u2011millimeter accuracy<\/td>Stable grasp of ultra\u2011stiff guidewires and devices<\/td><\/tr>
Haptic Feedback<\/strong><\/td>Low\u2011latency force feedback<\/td>Shortens learning curve; ensures patient safety<\/td><\/tr>
Surgical Team<\/strong><\/td>Single\u2011person synchronous control<\/td>Reduces team size and coordination complexity<\/td><\/tr>
Design<\/strong><\/td>Bionic, natural interactive handle<\/td>Replicates traditional TAVR push\u2011pull\/rotation techniques<\/td><\/tr>
Future Integration<\/strong><\/td>Compatible with 5G for remote surgery<\/td>Enables decentralization of high\u2011quality care<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Context<\/th><\/tr><\/thead>
China TAVR Market Size<\/strong><\/td>\u00a58\u201110\u202fbillion<\/strong> (\u2248\u202fUS$1.1\u20111.4\u202fB) (2025)<\/td>Growing at 25\u201130% CAGR<\/td><\/tr>
Annual TAVR Procedures<\/strong><\/td>~10,000 (2024)<\/td>Projected to reach 50,000 by 2030<\/td><\/tr>
Robotic Penetration<\/strong><\/td><5%<\/strong> of TAVR procedures<\/td>High growth potential with innovation pathway incentives<\/td><\/tr>
ReachTact Peak Sales<\/strong><\/td>\u00a51.2\u20111.8\u202fbillion<\/strong> (\u2248\u202fUS$170\u2011250\u202fM) by 2032<\/td>15\u201120% share of robotic\u2011assisted TAVR segment<\/td><\/tr>
Competitive Moat<\/strong><\/td>First\u2011mover<\/strong> in China; proprietary master\u2011slave + haptic tech<\/td>3\u2011year NMPA innovation exclusivity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n